Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma
详细信息 查看全文
- 作者：Lei Yang (14497)
WeiQi Rong (24497)
Ting Xiao (14497)
Ying Zhang (14497)
Bin Xu (34497)
Yu Liu (14497)
LiMing Wang (24497)
Fan Wu (24497)
Jun Qi (44497)
XiuYing Zhao (54497)
HongXia Wang (34497)
NaiJun Han (14497)
SuPing Guo (14497)
JianXiong Wu (24497)
YanNing Gao (14497)
ShuJun Cheng (14497) - 关键词：hepatocellular carcinoma (HCC) ; secretome ; biomarker ; MMP1 ; OPN ; PSG9
- 刊名：Science China Life Sciences
- 出版年：2013
- 出版时间：July 2013
- 年：2013
- 卷：56
- 期：7
- 页码：638-646
- 全文大小：622KB
- 参考文献：1. Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61: 69-0 CrossRef
2. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009, 27: 6550-557 CrossRef
3. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg, 2006, 243: 229-35 CrossRef
4. Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol, 2007, 14: 2337-347 CrossRef
5. Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, 2010, 59: 1687-693 CrossRef
6. States D J, Omenn G S, Blackwell T W, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol, 2006, 24: 333-38 CrossRef
7. Meng R, Gormley M, Bhat V B, et al. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics, 2011, 75: 366-74 CrossRef
8. Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics, 2010, 73: 2291-305 CrossRef
9. Planque C, Kulasingam V, Smith C R, et al. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics, 2009, 8: 2746-758 CrossRef
10. Polisetty R V, Gupta M K, Nair S C, et al. Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins. J Proteomics, 2011, 74: 1918-925 CrossRef
11. Xiao T, Ying W, Li L, et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics, 2005, 4: 1480-486 CrossRef
12. Zhang Y, Xu B, Liu Y, et al. The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics, 2012, 12: 1883-891 CrossRef
13. Lechner J F, LaVeck M A. A serum-free method for culturing normal human bronchial epithelial cells at clonal density. J Tissue Cult Methods, 1985, 9: 43-8 CrossRef
14. Shen Z, Li P, Ni R J, et al. Label-free quantitative proteomics analysis of etiolated maize seedling leaves during greening. Mol Cell Proteomics, 2009, 8: 2443-460 CrossRef
15. Sun H, Fang H, Chen T, et al. GOFFA: gene ontology for functional analysis—a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics, 2006, 7(Suppl 2): S23 CrossRef
16. Wu S, Wan P, Li J, et al. Multi-modality of pI distribution in whole proteome. Proteomics, 2006, 6: 449-55 CrossRef
17. Omenn G S, States D J, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics, 2005, 5: 3226-245 CrossRef
18. Anderson N L, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics, 2004, 3: 311-26 CrossRef
19. Chinese Human Liver Proteome Profiling Consortium. First insight into the human liver proteome from PROTEOME(SKY)-LIVER(Hu) 1.0, a publicly available database. J Proteome Res, 2010, 9: 79-4 CrossRef
20. Lin L, Amin R, Gallicano G I, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene, 2009, 28: 961-72 CrossRef
21. Pavlou M P, Diamandis E P. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics, 2010, 73: 1896-906 CrossRef
22. Sun S, Xu M Z, Poon R T, et al. Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J Proteome Res, 2010, 9: 70-8 CrossRef
23. Luk J M, Lam C T, Siu A F, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics, 2006, 6: 1049-057 CrossRef
24. Murata M, Matsuzaki K, Yoshida K, et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology, 2009, 49: 1203-217 CrossRef
25. Takafuji V, Forgues M, Unsworth E, et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene, 2007, 26: 6361-371 CrossRef
26. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012, 55: 483-90 CrossRef
27. Sun J, Xu H M, Zhou H J, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2010, 136: 1- CrossRef
28. Salahshor S, Goncalves J, Chetty R, et al. Differential gene expression profile reveals deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer, 2005, 5: 66 CrossRef
29. Lisboa F A, Warren J, Sulkowski G, et al. Pregnancy-specific glycoprotein 1 induces endothelial tubulogenesis through interaction with cell surface proteoglycans. J Biol Chem, 2011, 286: 7577-586 CrossRef
30. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010, 141: 52-7 CrossRef
31. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology, 2005, 129: 2064-075 CrossRef
32. Liu D, Guo H, Li Y, et al. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS ONE, 2012, 7: e31251 CrossRef
33. Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer, 2008, 8: 77 CrossRef
34. Li M, Xiao T, Zhang Y, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer, 2010, 69: 341-47 CrossRef - 作者单位：Lei Yang (14497)
WeiQi Rong (24497)
Ting Xiao (14497)
Ying Zhang (14497)
Bin Xu (34497)
Yu Liu (14497)
LiMing Wang (24497)
Fan Wu (24497)
Jun Qi (44497)
XiuYing Zhao (54497)
HongXia Wang (34497)
NaiJun Han (14497)
SuPing Guo (14497)
JianXiong Wu (24497)
YanNing Gao (14497)
ShuJun Cheng (14497)
14497. State Key Laboratory of Molecular Oncology, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, Cancer Institute (Hospital), Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100021, China
24497. Department of Abdominal Surgery, Cancer Institute (Hospital), Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100021, China
34497. National Center of Biomedical Analysis, Beijing, 100850, China
44497. Clinical Laboratory, Cancer Institute (Hospital), Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100021, China
54497. Clinical Laboratory, Beijing You’an Hospital, Capital Medical University, Beijing, 100069, China
文摘
For successful therapy, hepatocellular carcinoma (HCC) must be detected at an early stage. Herein, we used a proteomic approach to analyze the secretory/releasing proteome of HCC tissues to identify plasma biomarkers. Serum-free conditioned media (CM) were collected from primary cultures of cancerous tissues and surrounding noncancerous tissues. Proteomic analysis of the CM proteins permitted the identification of 1365 proteins. The enriched molecular functions and biological processes of the CM proteins, such as hydrolase activity and catabolic processes, were consistent with the liver being the most important metabolic organ. Moreover, 19% of the proteins were characterized as extracellular or membrane-bound. For validation, secretory proteins involved in transforming growth factor-β signaling pathways were validated in plasma samples. Alphafetoprotein (AFP), metalloproteinase (MMP)1, osteopontin (OPN), and pregnancy-specific beta-1-glycoprotein (PSG)9 were significantly increased in HCC patients. The overall performance of MMP1 and OPN in the diagnosis of HCC remained greater than that of AFP. In addition, this study represents the first report of MMP1 as a biomarker with a higher sensitivity and specificity than AFP. Thus, this study provides a valuable resource of the HCC secretome with the potential to investigate serological biomarkers. MMP1 and OPN could be used as novel biomarkers for the early detection of HCC and to improve the sensitivity of biomarkers compared with AFP.